Induced Overexpression of March-1 in Human Macrophages Altered to M2 Phenotype for Suppressing Inflammation Process Publisher

Summary: Can MARCH-1 gene transduction reduce inflammation? This study found that it enhances the M2 macrophage phenotype, lowering pro-inflammatory cytokines. A potential therapy for inflammation? #Macrophages #Immunology

Zangeneh Z¹ ; Khamisipour G² ; Andalib AR^{1, 3}
Source: Iranian Journal of Basic Medical Sciences Published:2022

Abstract

Objective(s): The M1 macrophage is characterized by enhanced pro-inflammatory cytokines production, whereas macrophage (M2) has anti-inflammatory features. Macrophage polarization as a therapeutic target for controlling immune responses could be performed by gene transduction to control the regulation of exaggerated innate/adaptive immune responses. Materials and Methods: Macrophages were prepared from THP-1 cell line and human monocytes that were transduced with (Membrane-Associated RING-CH-type finger) MARCH-1 viral lentivector produced in HEK-293T cells. RT-PCR and Western blotting confirmed MARCH-1 gene transduction. Cytokine production, CD markers assay, macrophage phagocytosis potential activity and mixed leukocyte reaction (MLR) with CFSE were performed for M1/M2 plasticity. Results: The mean fluorescent intensity of HLA-DR and CD64 expression reduced in MARCH-1+ transduced macrophage population. However, CD206 and CD163 expression increased in these macrophages. The concentrations of IL-6, TNF-α and iNOS were decreased in MARCH-1 transduced cells, and TGF-β production showed an augmentation in concentration. Western blotting and real-time PCR measurement confirmed that the expression levels of MARCH-1 protein and arginase-1 enzyme were increased in transduced macrophages. Conclusion: The anti-inflammatory features of MARCH-1 revealed the reduced levels of proinflammatory factors and maintained M2 phenotype characterized by high levels of scavenger receptors. Therefore, targeting MARCH-1 in monocytes/macrophages could represent a new autologous cell-based therapies strategy for inflammatory conditions. © 2022 Mashhad University of Medical Sciences. All rights reserved.